<?xml version='1.0' encoding='utf-8'?>
<document id="30633968"><sentence text="Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats."><entity charOffset="45-54" id="DDI-PubMed.30633968.s1.e0" text="magnesium" /><entity charOffset="81-92" id="DDI-PubMed.30633968.s1.e1" text="montelukast" /><entity charOffset="94-107" id="DDI-PubMed.30633968.s1.e2" text="rosiglitazone" /><entity charOffset="109-121" id="DDI-PubMed.30633968.s1.e3" text="pioglitazone" /><entity charOffset="123-134" id="DDI-PubMed.30633968.s1.e4" text="repaglinide" /><entity charOffset="139-149" id="DDI-PubMed.30633968.s1.e5" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e0" e2="DDI-PubMed.30633968.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e0" e2="DDI-PubMed.30633968.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e0" e2="DDI-PubMed.30633968.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e0" e2="DDI-PubMed.30633968.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e0" e2="DDI-PubMed.30633968.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e0" e2="DDI-PubMed.30633968.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e1" e2="DDI-PubMed.30633968.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e1" e2="DDI-PubMed.30633968.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e1" e2="DDI-PubMed.30633968.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e1" e2="DDI-PubMed.30633968.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e1" e2="DDI-PubMed.30633968.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e2" e2="DDI-PubMed.30633968.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e2" e2="DDI-PubMed.30633968.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e2" e2="DDI-PubMed.30633968.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e2" e2="DDI-PubMed.30633968.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e3" e2="DDI-PubMed.30633968.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e3" e2="DDI-PubMed.30633968.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e3" e2="DDI-PubMed.30633968.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e4" e2="DDI-PubMed.30633968.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s1.e4" e2="DDI-PubMed.30633968.s1.e5" /></sentence><sentence text="Saroglitazar, a PPAR αҮ agonist, is currently undergoing global development for the treatment of NASH and other indications" /><sentence text=" Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC50: 2" /><sentence text="9 μM)" /><sentence text=" The aim was to carry out drug-drug interaction (DDI) studies in Wistar rats using saroglitazar (perpetrator drug) with five CYP2C8 substrates" /><sentence text=" Also, the in vitro CYP2C8 inhibitory potential of saroglitazar in rat liver microsomes (RLM) was evaluated to justify use of preclinical model" /><sentence text=" The oral pharmacokinetics of various CYP2C8 substrates; montelukast, rosiglitazone, pioglitazone, repaglinide and intravenous pharmacokinetics of paclitaxel was assessed in the presence/absence of oral saroglitazar (4 mg/kg) in Wistar rats"><entity charOffset="57-68" id="DDI-PubMed.30633968.s7.e0" text="montelukast" /><entity charOffset="70-83" id="DDI-PubMed.30633968.s7.e1" text="rosiglitazone" /><entity charOffset="85-97" id="DDI-PubMed.30633968.s7.e2" text="pioglitazone" /><entity charOffset="99-110" id="DDI-PubMed.30633968.s7.e3" text="repaglinide" /><entity charOffset="147-157" id="DDI-PubMed.30633968.s7.e4" text="paclitaxel" /><entity charOffset="203-215" id="DDI-PubMed.30633968.s7.e5" text="saroglitazar" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e0" e2="DDI-PubMed.30633968.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e0" e2="DDI-PubMed.30633968.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e0" e2="DDI-PubMed.30633968.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e0" e2="DDI-PubMed.30633968.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e0" e2="DDI-PubMed.30633968.s7.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e0" e2="DDI-PubMed.30633968.s7.e5" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e1" e2="DDI-PubMed.30633968.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e1" e2="DDI-PubMed.30633968.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e1" e2="DDI-PubMed.30633968.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e1" e2="DDI-PubMed.30633968.s7.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e1" e2="DDI-PubMed.30633968.s7.e5" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e2" e2="DDI-PubMed.30633968.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e2" e2="DDI-PubMed.30633968.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e2" e2="DDI-PubMed.30633968.s7.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e2" e2="DDI-PubMed.30633968.s7.e5" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e3" e2="DDI-PubMed.30633968.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e3" e2="DDI-PubMed.30633968.s7.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e3" e2="DDI-PubMed.30633968.s7.e5" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e4" e2="DDI-PubMed.30633968.s7.e4" /><pair ddi="false" e1="DDI-PubMed.30633968.s7.e4" e2="DDI-PubMed.30633968.s7.e5" /></sentence><sentence text=" A separate study was performed to assess the oral pharmacokinetics of saroglitazar" /><sentence text=" Serial blood samples were collected from all studies and the harvested plasma were stored frozen until bioanalysis" /><sentence text=" LC-MS/MS was used for the analysis of various analytes; concentration data was subjected to noncompartmental pharmacokinetic analysis" /><sentence text=" Statistical tests (unpaired t-test) were employed to judge the level of DDI" /><sentence text=" Generally, the pharmacokinetics of CYP2C8 substrates was not affected by the concomitant intake of saroglitazar as judged by the overall exposure (AUC0-last and AUC0-inf) and elimination half-life" /><sentence text=" The CYP2C8 IC50 of 4" /><sentence text="5 μM in RLM for saroglitazar, supported the use of rats for this DDI study" /><sentence text=" In conclusion, pharmacokinetic data of diverse CYP2C8 substrates suggested that coadministration of saroglitazar did not cause clinically relevant DDI" /><sentence text="" /></document>